NCT03064854 2022-08-15PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC PatientsNovartisPhase 1 Terminated111 enrolled
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT02334748 2020-05-19A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 StudiesNovartisPhase 3 Completed31 enrolled 7 charts
NCT02911857 2018-08-20An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever SyndromesNovartisPhase 3 Completed4 enrolled 7 charts